Pharmabiz: Merck initiates pivotal phase 2b/3 trial of Tiespectus, an investigational bispecific tie2 agonist/VEGF inhibitor, to treat neovascular age-related macular degeneration Merck initiates pivotal phase 2b/3 trial of Tiespectus, an investigational bispecific tie2 agonist/VEGF inhibitor, to treat neovascular age-related macular degeneration: Rahway, N ... Merck initiates pivotal phase 2b/3 trial of Tiespectus, an investigational bispecific tie2 agonist/VEGF inhibitor, to treat neovascular age-related macular degeneration Seeking Alpha: EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration Nasdaq: 4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration 4D Molecular Therapeutics announced the enrollment of the first patients in the Phase 3 clinical trial, 4FRONT-1, for its product 4D-150, aimed at treating wet age-related macular degeneration (AMD). 4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration Seeking Alpha: Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration Business Insider: Ashvattha Therapeutics Announces Positive Topline 40-Week Phase 2 Results for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration Ashvattha Therapeutics Announces Positive Topline 40-Week Phase 2 Results for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
